Norinchukin Bank The Buys 16,514 Shares of Johnson & Johnson $JNJ

Key Points

• Norinchukin Bank increased its stake in Johnson & Johnson by 14.1% in the first quarter, holding a total of 133,974 shares valued at approximately $22.2 million.
• Johnson & Johnson's quarterly earnings showed EPS of $2.77, surpassing estimates, with revenue reaching $23.74 billion, a 5.8% increase year-over-year.
• The company recently declared a $1.30 quarterly dividend, translating to an annual yield of 2.9% and a payout ratio of 55.61%.

Norinchukin Bank The grew its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 14.1% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 133,974 shares of the company's stock after purchasing an additional 16,514 shares during the quarter. Norinchukin Bank The's holdings in Johnson & Johnson were worth $22,218,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Brighton Jones LLC lifted its stake in shares of Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after purchasing an additional 6,332 shares during the period. Hudson Value Partners LLC grew its stake in Johnson & Johnson by 2.5% in the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock worth $5,648,000 after purchasing an additional 1,022 shares during the period. Harvest Investment Services LLC purchased a new position in Johnson & Johnson during the fourth quarter valued at $255,000. MGO One Seven LLC boosted its holdings in shares of Johnson & Johnson by 10.8% during the 4th quarter. MGO One Seven LLC now owns 76,442 shares of the company's stock valued at $11,055,000 after buying an additional 7,454 shares in the last quarter. Finally, Burling Wealth Partners LLC bought a new position in shares of Johnson & Johnson in the 4th quarter worth about $3,908,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Wall Street Analysts Forecast Growth

JNJ has been the topic of a number of recent research reports. Guggenheim restated a "neutral" rating and issued a $167.00 price objective (up previously from $164.00) on shares of Johnson & Johnson in a report on Thursday, July 17th. Bank of America raised their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a research report on Thursday, July 17th. Erste Group Bank raised Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Wednesday, July 23rd. Leerink Partnrs downgraded Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Finally, Piper Sandler reiterated an "overweight" rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $174.50.

Johnson & Johnson Price Performance

NYSE JNJ opened at $178.5890 on Thursday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The company has a market capitalization of $430.10 billion, a price-to-earnings ratio of 19.10, a PEG ratio of 2.26 and a beta of 0.41. The stock has a 50-day moving average of $162.59 and a 200 day moving average of $158.87. Johnson & Johnson has a one year low of $140.68 and a one year high of $180.61.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter in the prior year, the firm earned $2.82 earnings per share. The firm's revenue for the quarter was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. Johnson & Johnson's dividend payout ratio is currently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.